Growing seedlings: For this technique pre-germinated seeds are sown between mid-/end-February and beginning of April and grown in nurseries. Seedlings are grown in tuffs with 3–5 plants/tuff and a seed density of 1.2–1.6 kg/1000 tuffs. A fastened germination is achieved by alternating high temperature during daytime (30 °C for 8 h) and lower temperature during nighttime (20 °C for 16 h). Before transplanting, the seedlings should be fertilized and acclimated to cold temperatures. Transplantation should start around Mid-April with row spacing of 42–50 cm (17–20 in) and plant spacing within rows of 25–30 cm. Vegetative propagation: Stolons (with several buds) of 10 cm should be planted from mid-April in a depth of 5–7 cm (2–2+3⁄4 in). Head cuttings are grown in nurseries starting between mid-May and mid-June. Growing tips with two leaf pairs are cut from the mother plant and treated with root-growth inducing hormones. Transplantation can be delayed in comparison to the growing seedling technique. Greenhouse
The stinging nettle can also be grown in controlled-environment agriculture systems, such as soil-less medium cultivations or aeroponics, which may achieve higher yields, standardize quality, and reduce harvesting costs and contamination. Sting and treatment
Urtica dioica produces its inflammatory effect on skin (stinging, burning sensation often called "contact urticaria") both by impaling the skin via spicules – causing mechanical irritation – and by biochemical irritants, such as histamine, serotonin, and acetylcholine, among other chemicals. Anti-itch drugs, usually in the form of creams containing antihistamines or hydrocortisone, may provide relief from nettle dermatitis.
Sebelipase alfa, sold under the brand name Kanuma,  is a recombinant form of  the enzyme lysosomal acid lipase (LAL) that is used as a medication for the treatment of lysosomal acid lipase deficiency (LAL-D). It is administered via intraveneous infusion. It was approved for medical use in the European Union and in the United States in 2015. Medical uses
Sebelipase alfa is indicated for long-term enzyme replacement therapy (ERT) in people of all ages with lysosomal acid lipase (LAL) deficiency. History
Sebelipase was developed by Synageva that became part of Alexion Pharmaceuticals in 2015. For its production, chickens are genetically modified to  produce the recombinant form of LAL (rhLAL) in their egg white. After extraction and purification it becomes available as the medication. On 8 December 2015 the FDA announced that its approval came from two centers: The Center for Drug Evaluation and Research (CDER) approved the human therapeutic application of the medication, while the Center for Veterinary Medicine (CVM) approved the application for a recombinant DNA construct in genetically engineered chicken to produce rhLAL in their egg whites. At the time it gained FDA approval Kanuma was the first only drug manufactured in chicken eggs and intended for use in humans.Sebelipase alfa is an orphan drug; its effectiveness was published after a phase 3 trial in 2015. The disease of LAL affects < 0.2 in 10,000 people in the EU. References
External links
"Sebelipase alfa". Drug Information Portal. U.S. National Library of Medicine.